SBIR reauthorization
This article was originally published in The Gray Sheet
Executive Summary
Medical device and other firms seeking Small Business Innovation Research program grant money could be majority-owned by venture capital outfits under the SBIR/STTR Reauthorization Act (S. 3362) approved by the Senate Committee on Small Business and Entrepreneurship July 30. A similar measure was passed by the full House on April 23 ("1The Gray Sheet," April 28, 2008, p. 13). Industry has complained that restrictions on SBIR grants for VC-funded firms have limited the utility of the government program that helps jump-start small company research. The Senate bill would allow no more than 18% of National Institutes of Health SBIR funds to go to firms that are majority owned by venture capitalists
You may also be interested in...
House Passes SBIR Reauthorization, Loosens Venture Capital Restrictions
A bill reauthorizing the Small Business Innovation Research (SBIR) program passed the House April 23. It would allow larger federal research and development grants to small companies and give the firms more flexibility in seeking funds from both federal agencies and venture capitalists
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.